PHOX2B and neuroblastoma: PHOX2B, as a validated neuroblastoma-specific gene, was assigned an extremely low BayesTS score (0.03), consistent with the preclinical safety testing of this therapy and supporting the capacity of BayesTS to prioritize valid cancer targets.